Thought Leadership
 
Email Page
Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
Thomas K. Hedemann, Jonathan M. Knowles
Axinn Update
January 13, 2020
Method of Treatment Eligibility
Aziz Burgy, Christopher M. Gallo, PhD
Intellectual Property Magazine
January 9, 2020
Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
Ricardo Camposanto, Thomas K. Hedemann, David K. Ludwig
Axinn Update
December 30, 2019
Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
Ted Mathias, Matthew S. Murphy, Nisan C. Zaghi
Axinn Update
December 19, 2019
Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference
Alexander V. Alfano, Chad A. Landmon
FDLI
December 18, 2019
Who’s Who Legal – Thought Leaders Competition
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider
Who’s Who Legal
December 2019
3 Strategies To Manage Case Scope In ANDA Patent Litigation
Aziz Burgy, Eric D. Dunbar, Christopher M. Gallo, PhD, Brett Garrison
Law360
December 10, 2019
Little Impact Post-Arthrex for Biologic Patents at the PTAB
Drew A. Hillier, Stacie L. Ropka, PhD
The Center for Biosimilars
December 3, 2019
U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
Jonathan M. Knowles, Chad A. Landmon
IPWatchdog
November 25, 2019
Fed Circ. Ruling May Affect Eligibility Of Life Sciences Patents
David K. Ludwig, Ted Mathias
Law360
November 21, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 20, 2019
Can The FDA Salvage Interchangeable Follow-On Biologics?
Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
November 19, 2019
Axinn IP Update: Section 287(c) Immunity Has Its Limits
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
November 18, 2019
Curing the Drug Label as Prior Art Malady at the PTAB
Aziz Burgy, Christopher M. Gallo, PhD
IPWatchdog
November 13, 2019
New Calif. Pay-For-Delay Law May Hurt Those It Aims To Help
Chantelle D. Ankerman, Chad A. Landmon
Law360
November 5, 2019
Let Me Ride: No Short-Cuts in the Antitrust Analysis of Ride Hailing
Daniel S. Bitton, David R. Pearl, Patrick Shaw**
CLA: Competition, Fall 2019, Vol 29, No. 2
Fall 2019
Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 9, 2019
Failure To Launch: The Patent Thicket Delay of US Biosimilars
Chantelle D. Ankerman, Ted Mathias, Stacie L. Ropka, PhD
Law360
October 9, 2019
Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
Alexander V. Alfano, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 4, 2019
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 1, 2019
Fed. Circ. Muddies Waters On Method-Of-Treatment Patents
Thomas K. Hedemann, David K. Ludwig
Law360
September 4, 2019
Fixing The Follow-On Insulin Regulatory Approval "Dead Zone"
Christopher M. Gallo, PhD, Chad A. Landmon
BioSimilar Development
September 4, 2019
Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
Ross E. Blau, Ted Mathias
Axinn Update
August 29, 2019
Can We Have Mergers Without Tears? Understanding the Basics of Merger Review
Michael L. Keeley
Our Curious Amalgam
August 26, 2019
Recent FDA Court Decision Shows Potential Impact of SCOTUS Deference Decision
Alexander V. Alfano, Chad A. Landmon
Bloomberg Law and Bloomberg Big Law Business
August 20, 2019
Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
August 19, 2019
How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy
Drew A. Hillier, Stacie L. Ropka, PhD
Biosimilar Development
July 23, 2019
What High Court's Kisor Ruling Means for FDA Decisions
Alexander V. Alfano, Chad A. Landmon
Law360
July 16, 2019
UnitedHealth-DaVita and Trends in Vertical Merger Enforcement
Adam Cella, Jeny M. Maier
AHLA PG Briefing
July 11, 2019
FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen
Jonathan M. Knowles, Chad A. Landmon
Bloomberg BNA Insights
June 27, 2019
How I Made Partner: Jeny Maier
Jeny M. Maier
Law.com
June 19, 2019
Judge Moves Aetna/CVS Deal Into Unchartered Tunney Act Waters
Lisl J. Dunlop, Jeny M. Maier
Bloomberg Law
June 4, 2019
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
Drew A. Hillier, Jonathan M. Knowles, Stacie L. Ropka, PhD
BioProcess International
May 17, 2019
Information Exchange Counseling in the Digital Age
Kail J. Jethmalani
The Antitrust Counselor
May 15, 2019
Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics
Christopher M. Gallo, PhD, Jonathan M. Knowles, Stacie L. Ropka, PhD
Axinn Update
May 14, 2019
Who’s Who Legal – Thought Leaders Competition and Thought Leaders Global Elite
John D. Harkrider
Who’s Who Legal
May 9, 2019
Navigating Vertical Mergers in Healthcare Through a Shifting Enforcement Landscape
Lisl J. Dunlop, Cristina M. Fernandez
Competition Policy International
May 7, 2019
Antitrust Updates from Latin and South America
Kail J. Jethmalani
ABA Section of Antitrust Law
April 26, 2019
The Capitol Forum Thought Leaders Series
Lisl J. Dunlop, Jeny M. Maier
April 25, 2019
Competition in Display Ad Technology: A Retrospective Look at Google/Doubleclick and Google/Admob
Daniel S. Bitton, Stacie Soohyun Cho, Tal M. Elmatad, David R. Pearl
Competition Policy International
April 17, 2019
2018 Year-End Roundup of Federal Circuit Obviousness Decisions in Biopharma
Jonathan A. Harris, Drew A. Hillier, Nisan C. Zaghi
Westlaw Journal Pharmaceutical
April 9, 2019
Justices May Be Ready To Narrowly Overturn 'Auer'
Chad A. Landmon
Law360
March 28, 2019
FDA Doubles Down in Its Updated Biologics Naming Guidance
Jonathan M. Knowles, Chad A. Landmon
The Center for Biosimilars
March 19, 2019
Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.
Thomas K. Hedemann, Jonathan M. Knowles, Stacie L. Ropka, PhD
Axinn Update
March 18, 2019
Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed
Rebecca L. Clegg, Delphine Knight Brown, Joshua S. Reisberg
Axinn Update
March 5, 2019
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
Eric D. Dunbar, Chad A. Landmon
FDLI Update
March 1, 2019
Method-of-Treatment Patent Eligibility: Step 1 and Done?
Thomas K. Hedemann, David K. Ludwig
Law360
February 5, 2019
A Hard Choice for Abbreviated Biologics License Applicants
Drew A. Hillier, Ted Mathias, Stacie L. Ropka, PhD
Law360
February 4, 2019
Axinn IP Update: Federal Circuit Affirms No Public Use Via Implied Confidentiality
Alexander V. Alfano, Ryan A. Cook, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
January 30, 2019
Stem Cell Companies Beware: FDA May Come Knocking
Jonathan M. Knowles, Chad A. Landmon
Bloomberg BNA Insights
January 28, 2019
Axinn IP Update: U.S. Supreme Court Ruling Leaves On-Sale Bar Unchanged
Alexander V. Alfano, Chad A. Landmon, Stacie L. Ropka, PhD
Axinn Update
January 23, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Brandon Boxbaum
GCR Insight: E-Commerce Competition Enforcement Guide
January 10, 2019
Bringing Light to the DOJ’s Cartel Fine Methodology with the Auto Parts Plea Agreements
Daniel K. Oakes
The Antitrust Bulletin
December 1, 2018
Patent Dance Developments: A Tale of 2 Antibodies
Ted Mathias, Stacie L. Ropka, PhD, Nisan C. Zaghi
Law360
October 26, 2018
Axinn FDA Update: SUPPORT for Patients and Communities Act
Chad A. Landmon
Axinn Update
October 9, 2018
Sports and Labor Monopsonies: Learning from the Pros
Chris Brassfield**, Nicholas E.O. Gaglio
ABA Antitrust Law Monopoly Matters (Vol. 16, No. 2)
Fall 2018
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
Chad A. Landmon
ABA: Section of Intellectual Property Law
October 2, 2018
United States: Mergers
Mark D. Alexander
The Antitrust Review of the Americas 2019
September 24, 2018
FDA Focus: What Axinn's Practice Chair Is Watching
Chad A. Landmon
Law360
September 14, 2018
The CRISPR Tug of War
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
IPWatchdog
August 17, 2018
Vertical Healthcare Merger Review After United States v. AT&T, Inc.
Jeny M. Maier
AHLA Weekly
July 27, 2018
Antitrust in the Trump Administration: A Tough Enforcer That Believes in Limited Government
John D. Harkrider
ABA Antitrust Magazine
July 20, 2018
Connecting the Dots: Tracing the DOJ’s Inclusion of Indirect Commerce in Auto Parts Criminal Penalties
Daniel K. Oakes
ABA Antitrust Magazine
July 20, 2018
Beyond the Merits: Generic Company Defense Strategies
Joshua S. Reisberg
Pharmaceutical Executive
June 29, 2018
Integrating Trade Secrets into a Comprehensive IP Strategy
Jason Murata, John M. Tanski
Today's General Counsel
June 19, 2018
2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
Ross E. Blau, Jonathan A. Harris, Drew A. Hillier
Westlaw Journal
April 17, 2018
AHLA Antitrust Practice Group Alert
Adam Cella, Jeny M. Maier
American Health Lawyers Association
March 27, 2018
Chapter on Non-Prosecutorial Activities
Rachel J. Adcox, James A. Goldfeier, Kail J. Jethmalani, Kenina J. Lee
DOJ Civil Antitrust Practice and Procedure Manual
2018
Concentrated Benefits and Dispersed Costs Rent-Seeking by Incumbents Against Innovative and Disruptive Web Based Firms
Daniel S. Bitton, Stacie Soohyun Cho, John D. Harkrider
Douglas H. Ginsburg – An Antitrust Professor on the Bench Liber Amicorum Volume 1
March 1, 2018
Navigating the Jurisdiction of American Courts
Daniel S. Bitton, John DeQ. Briggs
February 2018
Unrung Bells and the Quick-Peek Order
Brooke J. Oppenheimer, Thomas G. Rohback
New York Law Journal
February 2, 2018
Re-Designing the American Antitrust Machine Part I: Treble Damages, Contribution and Claim Reduction
John DeQ. Briggs
(published in “Douglas H. Ginsburg, an Antitrust Professor on the Bench,” Liber Amicorum, by the Institute of Competition Law)
2018
Transatlantisch gebruik van verklaringen: medewerkingsplicht in de EU kan leiden tot verboden zelfincriminatie in de VS (Transatlantic use of witness statements: how EU cooperation obligations can lead to violation of the Fifth Amendment)
Daniel S. Bitton, Tal M. Elmatad
Tijdschrift Mededingingsrecht in de Praktijk
December 2017
The State of the Merger Efficiencies Defense After Anthem/Cigna and Aetna/Humana
Adam Cella
Health Care Liability & Litigation
November 2017
President Trump's Long-Awaited FTC Picks: Business as Usual
Kail J. Jethmalani
The Antitrust Counselor
November 2017
Sister Company Liability for Antitrust Conspiracies: Open Questions in Reconciling Copperweld and Twombly
Carol Xianxiao Liu
Perspectives in Antitrust
Fall 2017
Using Digital Tools in Litigation
Joshua S. Reisberg
Today's General Counsel
October 2017
Compliance Programs and Leniency Applications in Asian Jurisdictions
Brandon Boxbaum, Nicholas E.O. Gaglio, Kail J. Jethmalani, Jarod G. Taylor
Cartel & Criminal Practice Committee Newsletter
Fall 2017
United States: Mergers
Mark D. Alexander
The Antitrust Review of the Americas 2018
September 8, 2017
Cyber Ransoms: Mr. Smith Attacks HBO's Loot Train
Brooke J. Oppenheimer, Thomas G. Rohback
New York Law Journal
August 28, 2017
New Jersey District Court Judge Allows Tying Class Action Against the American Osteopathic Association to Proceed
Adam Cella
AHLA PG Alert
June 21, 2017
End of Laches Might Increase Declaratory Judgement Actions
Ryan A. Cook
IP Watchdog
June 19, 2017

View Archived Thought Leadership ›